2011 - TID Conference


CMV

2.1 - Is There a Role for CMV Vaccination in Transplant Patients?

Presenter: Paul, Griffiths, London, United Kingdom
Authors: Paul Griffiths


Is There a Role for CMV Vaccination in Transplant Patients?
Paul D. Griffiths, University College London, UK
Cytomegalovirus (CMV) can be transmitted from the donor to cause primary infection in a CMV seronegative recipient or reinfection in a CMV seropositive recipient. In addition, latent CMV in the recipient can reactivate post-transplant. The severity of these three types of infection can be ranked: primary is worse than reinfection which is worse than reactivation. This natural history of infection illustrates that immunity acquired from a previous infection can moderate the pathogenicity of CMV. This conclusion is supported by quantitative studies of CMV viral load where a greater burden (whether measured as duration of viraemia, peak viral load or area under the curve) is seen in those with primary infection, then reinfection with reactivation having the lowest values.
To determine if prior immunisation can do likewise, we randomised seronegative and seropositive recipients awaiting transplantation of a kidney or a liver to receive a placebo or a vaccine consisting of CMV glycoprotein B plus MF59 adjuvant. The results provide encouragement for this approach whose practicalities will be discussed.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi